🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,187

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

12 results for “osimertinib” Clear

  1. CARBOPLATIN, CISPLATIN, PEMETREXED, CARBOPLATIN, PEMETREXED, OSIMERTINIB, CISPLATIN, Telisotuzumab adizutecan, OSIMERTINIB, CARBOPLATIN, PEMETREXED

    AbbVie Deutschland GmbH & Co. KG

    Non-Squamous Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  2. CISPLATIN, CISPLATIN, Telisotuzumab adizutecan, OSIMERTINIB, PEMETREXED, CARBOPLATIN, CISPLATIN, AMIVANTAMAB, AMIVANTAMAB, CARBOPLATIN, CARBOPLATIN, PEMETREXED, OSIMERTINIB, PEMETREXED

    AbbVie Deutschland GmbH & Co. KG

    Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  3. Furmonertinib, AFATINIB, OSIMERTINIB, OSIMERTINIB, AFATINIB, AFATINIB

    ArriVent BioPharma

    Advanced or Metastatic Non-Small-Cell Lung Cancer With Epidermal Growth Factor Receptor P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations

    phase 3 small molecule active

    1 trial

  4. Osimertinib

    First Tracks Biotherapeutics

    Non-small Cell Carcinoma

    phase 3 small molecule active

    1 trial

  5. TAGRISSO 80 mg film-coated tablets, INFLIXIMAB, TAGRISSO 40 mg film-coated tablets, MYCOPHENOLATE MOFETIL, GLUCOSE, IMFINZI 50 mg/mL concentrate for solution for infusion.

    AstraZeneca AB

    Main cohort: Patients with unresected Stage I/II, lymph-node negative Non-small Cell Lung Cancer Osimertinib cohort: Open-label, Single arm for patients with unresected stage I/II, lymph done negative NSCLC harboring a sensitizing EGFR mutation

    phase 3 small molecule active

    1 trial

  6. ​Placebo to Osimertinib - Film-coated tablet - 40mg / 80mg, CARBOPLATIN, TAGRISSO 80 mg film-coated tablets, CISPLATIN, PEMETREXED, PEMETREXED, TAGRISSO 40 mg film-coated tablets

    AstraZeneca AB

    Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  7. -, -, ROXATIDINE , RANITIDINE , OSIMERTINIB , NIZATIDINE , SKB264, CIMETIDINE , FAMOTIDINE, COMBINATIONS, FAMOTIDINE , CARBOPLATIN , PARACETAMOL , PEMBROLIZUMAB , OSIMERTINIB, -

    Pharma Mar S.A.

    Advanced or Metastatic Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  8. OSIMERTINIB MESYLATE, OSIMERTINIB MESYLATE, PEMBROLIZUMAB, BL-B01D1

    Bristol-Myers Squibb / Pfizer EEIG

    Advance solid tumors

    phase 2 small molecule active

    1 trial

  9. osimertinib mesylate tablets and anlotinib hydrochloride capsules

    First Tracks Biotherapeutics

    Non Small Cell Lung Cancer

    phase 2 small molecule terminated

    1 trial

  10. Osimertinib

    PUMA BIOTECHNOLOGY, INC.

    Lung Cancer Metastatic

    phase 1 small molecule active

    1 trial

  11. PB101 plus EGFR-TKI including gefitinib, erlotinib, afatinib, or osimertinib

    PRECISION BIOSCIENCES INC

    Non-small Cell Lung Cancer

    phase 1 mab completed

    1 trial

  12. Phase I Clinical Study to Assess Safety and Efficacy of Repotrectinib Combined with Osimertinib in Patients with Advanced, Metastatic EGFR Mutant NSCLC (TOTEM).

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    Non-small cell lung cancer (NSCLC)

    phase 1 other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources